Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease

Jun Miyoshi, Tadakazu Hisamatsu, Katsuyoshi Matsuoka, Makoto Naganuma, Yuriko Maruyama, Kazuaki Yoneno, Kiyoto Mori, Hiroki Kiyohara, Kosaku Nanki, Susumu Okamoto, Tomoharu Yajima, Yasushi Iwao, Haruhiko Ogata, Toshifumi Hibi, Takanori Kanai

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Abstract

Background: We evaluated the clinical efficacy of adalimumab (ADA) for Crohn's disease (CD) and analyzed predictive factors for clinical remission and long-term prognosis. Methods: We retrospectively reviewed the medical records of 45 patients treated with ADA for CD at Keio University Hospital between October 2010 and March 2014. Clinical remission was defined as a Harvey-Bradshaw index of ≤ 4. Results: Twenty-eight of 45 patients (62.2%) achieved clinical remission at week 4. Among these 28 patients, 18 patients (64.3%) maintained clinical remission at week 26, and among these, 16 patients (88.9%) maintained clinical remission at week 52. Absence of a history of bowel resection and absence of prior anti-tumor necrosis factor (anti-TNF) therapy were significant predictive factors for clinical remission at week 4 upon multivariate logistic regression analyses. Younger age and a disease duration of ≤ 3 years correlated with clinical remission at week 26 upon univariate analyses. Patients without a history of bowel resection showed significantly better long-term prognosis than those with a history of bowel resection (p = 0.01). None of the patients contracted a serious infectious disease. Conclusions: Younger age, shorter duration of disease, being naive to anti-TNF antagonists, and absence of a history of bowel resection were associated with the efficacy of ADA in CD patients.

Original languageEnglish
Pages (from-to)130-136
Number of pages7
JournalDigestion
Volume90
Issue number2
DOIs
Publication statusPublished - 2014 Nov 7

Keywords

  • Adalimumab
  • Anti-tumor necrosis factor antagonist
  • Bowel resection
  • Clinical remission
  • Crohn's disease

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint Dive into the research topics of 'Early intervention with adalimumab may contribute to favorable clinical efficacy in patients with Crohn's disease'. Together they form a unique fingerprint.

Cite this